CDSCO approves durvalumab with FLOT for resectable gastric and GEJ cancer in India
Approval based on phase III MATTERHORN study supports perioperative use
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
AstraZeneca Pharma India
AstraZeneca India receives CDSCO approval for Durvalumab in combination with FLOT chemotherapy
AstraZeneca Pharma India, a global, science-led biopharmaceutical company, announces the Central Drugs Standard Control…
AstraZeneca Pharma India and Sun Pharma partner to help Hyperkalaemia patients in India
AstraZeneca Pharma India (‘AstraZeneca’), a leading science-led biopharmaceutical company and Sun Pharmaceutical Industries,…
AstraZeneca gains CDSCO approval for treatment of muscle-invasive bladder cancer
Durvalumab in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Durvalumab as adjuvant…
AstraZeneca Pharma India gains CDSCO approval for treating endometrial cancer in the country
Durvalumab in combination with carboplatin and paclitaxel is now also indicated for first-line treatment of adults with primary…
AstraZeneca gains CDSCO approval to import SZC for treating Hyperkalaemia in adult patients
This treatment can enhance hyperkalaemia management in adults, a condition characterised by elevated potassium levels that often…
CDSCO approves AstraZeneca’s anti-complement medicine Eculizumab
Eculizumab is approved in India to manage two rare diseases- Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic…
AstraZeneca India gets dual CDSCO approval for Trastuzumab deruxtecan
Additional indications for treatment of HER2 low breast cancer and HER2 positive gastric / gastro-oesophageal cancer
AstraZeneca receives CDSCO approval to import and market Andexanet Alfa in India
This drug is used for the treatment of critical bleeding conditions associated with use of novel anticoagulants (Factor Xa…
AstraZeneca’s Dapagliflozin gets extended indication approval from DCGI to treat heart failure in…
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted…